All Outputs (17)

IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients (2017)
Journal Article
Ahmad, N., Ammar, A., Storr, S. J., Green, A. R., Rakha, E., Ellis, I., & Martin, S. G. (2018). IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer Immunology, Immunotherapy, 67(4), https://doi.org/10.1007/s00262-017-2106-8

Macrophage-associated cytokines play an important role in cancer metastasis however the functions of Interleukins (IL) 6 and 10 in breast cancer (BC) progression and metastasis are not clear. In this study the roles of IL-6/IL-10 in regulating vascul... Read More about IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients.

Invasion in breast lesions: the role of the epithelial-stroma barrier (2017)
Journal Article
Rakha, E. A., Miligy, I., Gorringe, K. L., Toss, M. S., Green, A. R., Fox, S. B., …Ellis, I. O. (2018). Invasion in breast lesions: the role of the epithelial-stroma barrier. Histopathology, 72(7), 1075-1083. https://doi.org/10.1111/his.13446

Despite the significant biological, behavioural and management differences between ductal carcinoma in situ (DCIS) and invasive carcinoma of the breast, they share many morphological and molecular similarities. Differentiation of these two different... Read More about Invasion in breast lesions: the role of the epithelial-stroma barrier.

MYC regulation of Glutamine-Proline regulatory axis is key in Luminal B breast cancer (2017)
Journal Article
Craze, M. L., Cheung, H., Jewa, N., Coimbra, N. D., Soria, D., El-Ansari, R., …Green, A. R. (in press). MYC regulation of Glutamine-Proline regulatory axis is key in Luminal B breast cancer. British Journal of Cancer, https://doi.org/10.1038/bjc.2017.387

Background: Altered cellular metabolism is a hallmark of cancer and some are reliant on Glutamine for sustained proliferation and survival. We hypothesise that the Glutamine-Proline regulatory axis has a key role in Breast cancer (BC) in the highly p... Read More about MYC regulation of Glutamine-Proline regulatory axis is key in Luminal B breast cancer.

Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer (2017)
Journal Article
Naidoo, K., Wai, P. T., Maguire, S. L., Daley, F., Haider, S., Kriplani, D., …Natrajan, R. (2018). Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer. Molecular Cancer Therapeutics, 17(1), 306-315. https://doi.org/10.1158/1535-7163.mct-17-0760

Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. We therefore aimed to assess t... Read More about Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer.

Checkpoint kinase 1 expression predicts poor prognosis in Nigerian breast cancer patients (2017)
Journal Article
Ebili, H. O., Iyawe, V. O., Adeleke, K. R., Salami, B. A., Banjo, A. A., Nolan, C., …Agboola, A. O. J. (2018). Checkpoint kinase 1 expression predicts poor prognosis in Nigerian breast cancer patients. Molecular Diagnosis and Therapy, 22(1), 79-90. https://doi.org/10.1007/s40291-017-0302-z

Rho-GTPase activating-protein 18: A biomarker associated with good prognosis in invasive breast cancer (2017)
Journal Article
Aleskandarany, M. A., Sonbul, S. N., Surridge, R., Mukherjee, A., Caldas, C., Diez-Rodriguez, M., …Rakha, E. A. (2017). Rho-GTPase activating-protein 18: A biomarker associated with good prognosis in invasive breast cancer. British Journal of Cancer, 117(8), 1176-1184. https://doi.org/10.1038/bjc.2017.261

© 2017 Cancer Research UK. All rights reserved. Background:The prognostic value of lymphovascular invasion (LVI) in breast cancer (BC) has been demonstrated in several independent studies. However, identification of driver molecules for LVI remains a... Read More about Rho-GTPase activating-protein 18: A biomarker associated with good prognosis in invasive breast cancer.

Altered glutamine metabolism in breast cancer: subtype dependencies and alternative adaptations (2017)
Journal Article
El Ansari, R., McIntyre, A., Craze, M. L., Ellis, I. O., Rakha, E. A., & Green, A. R. (in press). Altered glutamine metabolism in breast cancer: subtype dependencies and alternative adaptations. Histopathology, https://doi.org/10.1111/his.13334

Cancer cells must alter their metabolism in order to satisfy the demands of necessary energy and cellular building blocks. These metabolic alterations are mediated by many oncogenic changes that affect cellular signalling pathways, which result in su... Read More about Altered glutamine metabolism in breast cancer: subtype dependencies and alternative adaptations.

Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review (2017)
Journal Article
Toss, M., Miligy, I., Thompson, A., Khout, H., Green, A., Ellis, I., & Rakha, E. (2017). Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review. Breast, 35, 151-156. doi:10.1016/j.breast.2017.07.012

The high proportion of ductal carcinoma in situ (DCIS) presented in mammographic screening and the relatively low risk of progression to invasive disease have raised questions related to overtreatment. Following a review of current DCIS management pr... Read More about Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review.

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers (2017)
Journal Article
Klimov, S., Rida, P. C., Aleskandarany, M. A., Green, A. R., Ellis, I. O., Janssen, E. A., …Aneja, R. (2017). Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers. British Journal of Cancer, 117(6), 826-834. https://doi.org/10.1038/bjc.2017.224

Background: Although distant metastasis (DM) in breast cancer (BC) is the most lethal form of recurrence and the most common underlying cause of cancer related deaths, the outcome following the development of DM is related to the site of metastasis.... Read More about Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.

FOXP1 expression correlates with better prognosis in invasive breast cancer including the ER-positive luminal subtype (2017)
Conference Proceeding
Joseph, C., Craze, M. L., Nolan, C., Diez-Rodriguez, M., Green, A. R., Rakha, E., …Mukherjee, A. (2017). FOXP1 expression correlates with better prognosis in invasive breast cancer including the ER-positive luminal subtype.

Background: Fork head box P1 (FOXP1) is a FOX family transcription factor influencing ERα;-regulated transcription by interaction with the ERα; related pioneer factor FOXA1. Altered FOXP1 expression is seen in breast and prostate cancers. This study... Read More about FOXP1 expression correlates with better prognosis in invasive breast cancer including the ER-positive luminal subtype.

Elevated expression of STK3 mRNA and protein is associated with poor outcome in invasive breast cancer (2017)
Conference Proceeding
Ojiegbe, S., Joseph, C., Provenzano, E., Caldas, C., Nolan, C., Green, A., …Mukherjee, A. (2017). Elevated expression of STK3 mRNA and protein is associated with poor outcome in invasive breast cancer.

Purpose of the study: The mammalian sterile 20-like kinase (MST2/STK3) and its close homologue MST1(STK4) are members of the germinal centre kinase group II (GCK II) family of mitogen-activated protein kinases (MAPK). High STK3 expression is known to... Read More about Elevated expression of STK3 mRNA and protein is associated with poor outcome in invasive breast cancer.

An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation (2017)
Journal Article
Candido Dos Reis, F. J., Wishart, G. C., Dicks, E. M., Greenberg, D., Rashbass, J., Schmidt, M. K., …Pharoah, P. D. (2017). An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Research, 19(1), Article 58. https://doi.org/10.1186/s13058-017-0852-3

BACKGROUND: PREDICT is a breast cancer prognostic and treatment benefit model implemented online. The overall fit of the model has been good in multiple independent case series, but PREDICT has been shown to underestimate breast cancer specific morta... Read More about An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation.

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections (2017)
Journal Article
Muftah, A. A., Aleskandarany, M. A., Al-kaabi, M. M., Sonbul, S. N., Diez-Rodriguez, M., Nolan, C. C., …Green, A. R. (2017). Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. Breast Cancer Research and Treatment, 164(2), 341-348. https://doi.org/10.1007/s10549-017-4270-0

Background: Although the prognostic value of Ki67 in breast cancer is well documented, using optimal cut-points for patient stratification, reproducibility of the scoring and interpretation of the results remain a matter of debate particularly when u... Read More about Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.

Phenotypic characterization of breast cancer: the role of CDC42 (2017)
Journal Article
Chrysanthou, E., Gorringe, K. L., Joseph, C., Craze, M. L., Nolan, C. C., Diez-Rodriguez, M., …Mukherjee, A. (2017). Phenotypic characterization of breast cancer: the role of CDC42. Breast Cancer Research and Treatment, 164(2), https://doi.org/10.1007/s10549-017-4267-8

Purpose: The molecular landscape of breast cancer (BC), especially of the Luminal A subtype, remains to be fully delineated. Transcriptomic data shows that Luminal A tumours are enriched for aberrant expression of genes in the cell division control 4... Read More about Phenotypic characterization of breast cancer: the role of CDC42.

Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma (2017)
Journal Article
Sonbul, S. N., Gorringe, K. L., Aleskandarany, M. A., Mukherjee, A., Green, A. R., Ellis, I. O., & Rakha, E. A. (2017). Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. Journal of Pathology: Clinical Research, 3(2), 105-114. https://doi.org/10.1002/cjp2.65

Some previous studies have reported that the chemokine (C-C motif) receptor 7 (CCR7) plays a role in breast cancer, is associated with lymph node metastasis and drives the site of distant metastasis. However, the impact of its expression on patient o... Read More about Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma.

Prognostic significance of tumour infiltrating B-Lymphocytes in breast ductal carcinoma in situ (2017)
Journal Article
Miligy, I., Mohan, P., Gaber, A., Aleskandarany, M. A., Nolan, C. C., Diez‐Rodriguez, M., …Rakha, E. A. (2017). Prognostic significance of tumour infiltrating B-Lymphocytes in breast ductal carcinoma in situ. Histopathology, 71(2), 258-268. https://doi.org/10.1111/his.13217

Aims: Tumour?infiltrating lymphocytes (TILs) are an important component of the immune response to cancer and have a prognostic value in breast cancer. Although several studies have investigated the role of T lymphocytes in breast cancer, the role of... Read More about Prognostic significance of tumour infiltrating B-Lymphocytes in breast ductal carcinoma in situ.

Clinical impact of tumor DNA repair expression and T-cell infiltration in breast cancers (2017)
Journal Article
Green, A. R., Aleskandarany, M. A., Ali, R., Hodgson, E. G., Atabani, S., De Souza, K., …Madhusudan, S. (2017). Clinical impact of tumor DNA repair expression and T-cell infiltration in breast cancers. Cancer Immunology Research, 5(4), 292-299. https://doi.org/10.1158/2326-6066.CIR-16-0195

© 2017 American Association for Cancer Research. Impaired DNA repair drives mutagenicity, which increases neoantigen load and immunogenicity. We investigated the expression of proteins involved in the DNA damage response (ATM, Chk2), double-strand br... Read More about Clinical impact of tumor DNA repair expression and T-cell infiltration in breast cancers.